Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Seifert

Showing results (31-40 of 145) with videos related to

Pageof 15
Sort By:
Oncology Research and Treatment|August 5, 2021
Elective Discontinuation of CDK4/6 Inhibitors in Patients with Metastatic Hormone Receptor-Positive, Her-2-Negative Breast Cancer: A Retrospective Single-Center ExperienceThomas Decker, Robert Seifert, Matthias Bichler, et al.
Seminars in Nuclear Medicine|November 7, 2022
Molecular Imaging of Lymphoma: Future Directions and PerspectivesKelsey L Pomykala, Wolfgang P Fendler, Ophir Vermesh, et al.
Theranostics|August 15, 2019
Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving <sup>177</sup>Lu-PSMA-617Katharina Kessel, Robert Seifert, Michael Schäfers, et al.
Clinical Nuclear Medicine|June 16, 2026
Parathyroid Carcinoma Mimicking a Parathyroid Adenoma on [18F]F-Choline-PET With Occult MetastasesCarola M Bregenzer, Roman Trepp, Florian Dammann, et al.
Radiology|December 11, 2019
<sup>18</sup>F-FDG PET/CT Uptake Classification in Lymphoma and Lung Cancer by Using Deep Convolutional Neural NetworksLudovic Sibille, Robert Seifert, Nemanja Avramovic, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 15, 2022
Is <sup>18</sup>F-FDG PET Needed to Assess <sup>177</sup>Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center AnalysisRobert Seifert, Tugce Telli, Boris Hadaschik, et al.
PET Clinics|May 3, 2024
Prostate-specific Membrane Antigen: DiagnosticsIan L Alberts, Robert Seifert, Rudolf A Werner, et al.
World Journal of Nuclear Medicine|December 23, 2020
Do fasting or high caloric drinks affect the physiological uptake of fluorine-18 prostate-specific membrane antigen-1007 in liver and bowel?Kambiz Rahbar, Ali Afshar-Oromieh, Robert Seifert, et al.
Nuklearmedizin. Nuclear Medicine|August 29, 2024
Prognostic value of pretherapeutic 68Ga-PSMA-11-PET based imaging parameters in mCRPC patients treated with PSMA radioligandsLaya Rahbar Nikoukar, Robert Seifert, David Ventura, et al.
Cancers|August 7, 2021
Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future PerspectivesKonstantin Egon Seifert, Robert Seifert, Katharina Kessel, et al.
Pageof 15

Showing results (31-40 of 145) with videos related to

Sort By:
Pageof 15
Oncology Research and Treatment|August 5, 2021
Elective Discontinuation of CDK4/6 Inhibitors in Patients with Metastatic Hormone Receptor-Positive, Her-2-Negative Breast Cancer: A Retrospective Single-Center ExperienceThomas Decker, Robert Seifert, Matthias Bichler, et al.
Seminars in Nuclear Medicine|November 7, 2022
Molecular Imaging of Lymphoma: Future Directions and PerspectivesKelsey L Pomykala, Wolfgang P Fendler, Ophir Vermesh, et al.
Theranostics|August 15, 2019
Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving <sup>177</sup>Lu-PSMA-617Katharina Kessel, Robert Seifert, Michael Schäfers, et al.
Clinical Nuclear Medicine|June 16, 2026
Parathyroid Carcinoma Mimicking a Parathyroid Adenoma on [18F]F-Choline-PET With Occult MetastasesCarola M Bregenzer, Roman Trepp, Florian Dammann, et al.
Radiology|December 11, 2019
<sup>18</sup>F-FDG PET/CT Uptake Classification in Lymphoma and Lung Cancer by Using Deep Convolutional Neural NetworksLudovic Sibille, Robert Seifert, Nemanja Avramovic, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 15, 2022
Is <sup>18</sup>F-FDG PET Needed to Assess <sup>177</sup>Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center AnalysisRobert Seifert, Tugce Telli, Boris Hadaschik, et al.
PET Clinics|May 3, 2024
Prostate-specific Membrane Antigen: DiagnosticsIan L Alberts, Robert Seifert, Rudolf A Werner, et al.
World Journal of Nuclear Medicine|December 23, 2020
Do fasting or high caloric drinks affect the physiological uptake of fluorine-18 prostate-specific membrane antigen-1007 in liver and bowel?Kambiz Rahbar, Ali Afshar-Oromieh, Robert Seifert, et al.
Nuklearmedizin. Nuclear Medicine|August 29, 2024
Prognostic value of pretherapeutic 68Ga-PSMA-11-PET based imaging parameters in mCRPC patients treated with PSMA radioligandsLaya Rahbar Nikoukar, Robert Seifert, David Ventura, et al.
Cancers|August 7, 2021
Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future PerspectivesKonstantin Egon Seifert, Robert Seifert, Katharina Kessel, et al.
Pageof 15